SMAD3 and Alzheimer disease: Our human brain snRNAseq data analyzed by NicheNet51 predicted interactions with pericytic targets and astrocytic ligands, of which we prioritized SMAD3-VEGFA molecular pair perturbed in AD brains, where former is also associated with antemortem AD outcomes.